Quince Therapeutics Inc.

06/11/2026 | Press release | Distributed by Public on 06/11/2026 15:07

Proxy Results (Form 8-K)

Item 5.07

Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of Quince Therapeutics, Inc. (the "Company") was held online via live webcast on June 11, 2026 (the "Annual Meeting"). At the Annual Meeting, there were present, in person virtually or by proxy, holders of 6,255,339 shares of common stock, or approximately 38.37% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting is set forth below:

Proposal One - Election of Directors

The Company's stockholders approved the election of one Class I director to the Board of Directors to serve until the 2029 annual meeting of stockholders and until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal. The results of such vote were:

Nominee Votes For Votes Withheld Broker Non-Votes

June Bray

2,430,964 216,735 3,607,640

Proposal Two - Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split

The Company's stockholders approved the amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's issued and outstanding common stock at a ratio ranging from one-for-ten (1-for-10) to one-for-one hundred (1-for-100) with such reverse stock split to be effected at such time and date, if at all, as determined by the Company's board of directors in its sole discretion. The results of such vote were:

Votes For

Votes Against

Abstentions

4,715,574 1,517,896 21,866

Proposal Three - Ratification of Selection of Independent Registered Accounting Firm

The Company's stockholders ratified the selection of BDO USA, P.C. as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026. The results of such vote were:

Votes For

Votes Against

Abstentions

6,080,608 111,522 63,207

Proposal Four - Approval, on an advisory basis, of the compensation of the Company's named executive officers

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. The results of such vote were:

Votes For

Votes Against

Abstentions

Broker Non-Votes

2,504,778 116,876 26,044 3,607,641

Proposal Five - Adjournment of Annual Meeting

The Company's stockholders approved the adjournment or postponement of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in favor of the foregoing proposals. The results of such vote were:

Votes For

Votes Against

Abstentions

5,236,032 987,376 31,929
Quince Therapeutics Inc. published this content on June 11, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 11, 2026 at 21:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]